| Duncan Chiropractic Group | |
|
8336 Hilton Rd Ste 100, Brighton, MI 48114-5015 | |
| (810) 225-2288 | |
| (810) 479-5854 |
| Full Name | Duncan Chiropractic Group |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 8336 Hilton Rd Ste 100, Brighton, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306395231 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | (* (Not Available)) | Primary |
| Provider Name | Corey J Laber |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1134157068 PECOS PAC ID: 1052381449 Enrollment ID: I20040731000307 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Provider Name | Gary L Carlini |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1821151036 PECOS PAC ID: 3476625757 Enrollment ID: I20080701000503 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Provider Name | Michael D Hilton |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1285930982 PECOS PAC ID: 7911180047 Enrollment ID: I20110325000748 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Provider Name | Kevin M Michalak |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1174831556 PECOS PAC ID: 1850576919 Enrollment ID: I20110505000048 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Provider Name | Kevin Patrick Jonca |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1720118722 PECOS PAC ID: 7416965520 Enrollment ID: I20140224000423 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Provider Name | Jason D Tagai |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1003079716 PECOS PAC ID: 0840567772 Enrollment ID: I20170525001011 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Provider Name | Ryan M Mercier |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1508525031 PECOS PAC ID: 6608267679 Enrollment ID: I20211230000116 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Duncan Chiropractic Group 8336 Hilton Rd Ste 100, Brighton, MI 48114-5015 Ph: () - | Duncan Chiropractic Group 8336 Hilton Rd Ste 100, Brighton, MI 48114-5015 Ph: (810) 225-2288 |
News Archive
By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
Geisinger Health System has completed the Centers for Medicare Services' (CMS) five-year Physician Group Practice (PGP) demonstration project, again achieving 100 percent on the program's quality measures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
› Verified 8 days ago
Jordan Clark, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 10192 Grand River Rd Ste 107, Brighton, MI 48116 Phone: 810-494-1900 | |
Advanced Computerized Chiropractic Chiropractor Medicare: Medicare Enrolled Practice Location: 8619 W Grand River Ave, Suite B, Brighton, MI 48116 Phone: 810-225-7350 | |
Jeffrey Ewing, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 5889 Whitmore Lake Rd Ste 3, Brighton, MI 48116 Phone: 810-227-7799 Fax: 810-227-8999 | |
Dr. Melissa Bornemann Osborn, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 7487 Grand River Rd, Brighton, MI 48114 Phone: 810-588-6314 Fax: 810-433-5979 | |
Dr. Anthony Paul Arena, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2209 Euler Rd, Suite 2, Brighton, MI 48114 Phone: 810-225-2866 Fax: 810-225-2871 | |
Dr. Kevin Michael Michalak, D.C Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 8685 W Grand River Ave, Brighton, MI 48116 Phone: 810-225-2288 | |
True Wellness Chiropractic Pc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2120 Grand River Anx, Suite 100, Brighton, MI 48114 Phone: 810-225-7191 Fax: 810-225-7192 |